Page 51 - BH-1-2

Brain & Heart RDN guided by novel blood pressure responses

Ablation at these sites may result in a rise in postoperative Consent for publication
BP, and this has been partially confirmed in our animal
experiments (unpublished data). Third, the results of the Written and verbal informed consents for the use of data
present study do not answer the exact benefit of RNS were obtained from the study subjects before the procedure.
guided by these BP patterns compared to anatomy-based Availability of data
RDN, and additional benefits should be further studied in
a well-designed randomized controlled clinical trial. Additional data are available from the corresponding
author upon reasonable request.
5. Conclusion
References
RNS-induced BP changes can be classified into five
patterns that provide precise guidance for RDN 1. Bhatt DL, Kandzari DE, O’Neill WW, et al., 2014, A controlled
procedures in humans. Ablation at sites with an elevated trial of renal denervation for resistant hypertension. N Engl
BP response during RNS resulted in an obvious BP J Med, 370: 1393–1401.
reduction in ABP. https://doi.org/10.1056/NEJMoa1402670

Acknowledgments 2. Desch S, Okon T, Heinemann D, et al., 2015, Randomized
sham-controlled trial of renal sympathetic denervation in
None. mild resistant hypertension. Hypertension, 65: 1202–1208.

Funding https://doi.org/10.1161/hypertensionaha.115.05283
3. Mathiassen ON, Vase H, Bech JN, et al., 2016, Renal
This work was supported, in part, by the Technology Star denervation in treatment-resistant essential hypertension.
Cultivation Program from the Science and Technology A randomized, SHAM-controlled, double-blinded 24-h
Association of Chongqing (Grant number: KJXX2017017), blood pressure-based trial. J Hypertens, 34: 1639–1647.
the Surface project from the Chongqing Municipal Health https://doi.org/10.1097/hjh.0000000000000977
Bureau (Grant number: 2016MSXM023), and the Kuanren
Talents Program of the Second Affiliated Hospital of 4. Kandzari DE, Bhatt DL, Brar S, et al., 2015, Predictors of
blood pressure response in the SYMPLICITY HTN-3 trial.
Chongqing Medical University.
Eur Heart J, 36: 219–227.
Conflict of interest https://doi.org/10.1093/eurheartj/ehu441
The authors declare no conflict of interest. 5. Bhatt DL, Vaduganathan M, Kandzari DE, et al., 2022, Long-
term outcomes after catheter-based renal artery denervation
Author contributions for resistant hypertension: Final follow-up of the randomised
SYMPLICITY HTN-3 Trial. Lancet, 400: 1405–1416.
Conceptualization: Yuehui Yin
Data curation: Zhenhong Ou, Dan Li, Tianli Xia, Huang https://doi.org/10.1016/s0140-6736(22)01787-1
Zhou, Xue Kuang, Chunxia Gan 6. Kandzari DE, Böhm M, Mahfoud F, et al., 2018, Effect of
Formal analysis: Zhenhong Ou, Kun Cui, Hao Zhou, Hang renal denervation on blood pressure in the presence of
Liu, Yunlin Chen antihypertensive drugs: 6-month efficacy and safety results
Funding acquisition: Yuhehui Yin from the SPYRAL HTN-ON MED proof-of-concept
Investigation: Huaan Du, Weijie Chen, Bo Zhang, Wenjiang randomised trial. Lancet, 391: 2346–2355.
Chen, Mingyang Xiao, Changzhi Zhang, Jie Yang https://doi.org/10.1016/s0140-6736(18)30951-6
Methodology: Yuehui Yin
Resources: Yuehui Yin, Zengzhang Liu 7. Bohm M, Kario K, Kandzari DE, et al., 2020, Efficacy
Supervision: Yuhui Yin, Kamsang Woo, Zrenner Bernhard of catheter-based renal denervation in the absence of
antihypertensive medications (SPYRAL HTN-OFF MED
Visualization: Zhenhong Ou, Yunlin Chen, Hao Zhou, Pivotal): A multicentre, randomised, sham-controlled trial.
Hang Liu Lancet, 395: 1444–1451.
Writing – original draft: Zhenhong Ou
Writing – review and editing: Yuehui Yin https://doi.org/10.1016/s0140-6736(20)30554-7
8. Azizi M, Sanghvi K, Saxena M, et al., 2021, Ultrasound renal
Ethics approval and consent to participate denervation for hypertension resistant to a triple medication
All procedures were approved by the Ethics Committee pill (RADIANCE-HTN TRIO): A randomised, multicentre,
of the Second Affiliated Hospital of Chongqing Medical single-blind, sham-controlled trial. Lancet, 397: 2476–2486.
University (approval number: 2016-10). https://doi.org/10.1016/s0140-6736(21)00788-1

Volume 1 Issue 2 (2023) 9 https://doi.org/10.36922/bh.0384